Evolocumab for the treatment of heterozygous familial hypercholesterolemia in end-stage chronic kidney disease and dialysis

Nefrologia (Engl Ed). 2019 Mar-Apr;39(2):218-220. doi: 10.1016/j.nefro.2018.09.005. Epub 2018 Dec 10.

[Article in English, Spanish]

Authors

Silvia González Sanchidrián¹, Pedro Jesús Labrador Gómez², José Carlos Aguilar Aguilar², Elena Davin Carrero², Sandra Gallego Domínguez², Juan Ramón Gómez-Martino Arroyo²

Affiliations

¹ Servicio de Nefrología, Hospital San Pedro de Alcántara, Complejo Hospitalario Universitario de Cáceres, Cáceres, España. Electronic address: silvia_goz@hotmail.com.
² Servicio de Nefrología, Hospital San Pedro de Alcántara, Complejo Hospitalario Universitario de Cáceres, Cáceres, España.

PMID: 30545713
DOI: 10.1016/j.nefro.2018.09.005

No abstract available

Publication types

Case Reports
Letter

MeSH terms

Adult
Antibodies, Monoclonal, Humanized / therapeutic use*
Anticholesteremic Agents / therapeutic use*
Ezetimibe / therapeutic use
Humans
Hyperlipoproteinemia Type II / drug therapy*
Kidney Failure, Chronic / complications*
Kidney Failure, Chronic / therapy
Male
PCSK9 Inhibitors
Renal Dialysis*
Rosuvastatin Calcium / therapeutic use

Substances

Antibodies, Monoclonal, Humanized
Anticholesteremic Agents
PCSK9 Inhibitors
Rosuvastatin Calcium
PCSK9 protein, human
Ezetimibe
evolocumab